Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Lipp, RW; Kump, PK.
Recent therapy options of gastrointestinal neuroendocrine tumours
AUST J CLIN ENDOCR M. 2016; 9(1): 7-10.
[OPEN ACCESS]
Web of Science
- Führende Autor*innen der Med Uni Graz
- Lipp Rainer
- Co-Autor*innen der Med Uni Graz
- Constantini-Kump Patrizia
- Altmetrics:
- Abstract:
- Neuroendocrine tumors (NET) of gastroenteropancreatic (GEP) origin count to one of the orphan tumor diseases. Even though rare in annual incidence numbers the prevalence of this disease is the second most common in the gastrointestinal tract. In the last two decades somatostatin-analogues became the treatment of choice to treat symptomatic patients with GEP-NET with a low proliferation index of Ki67 <= 10%. Recently the antiproliferative effect of somatostatin-analogues has been demonstrated regardless of hormone production. In the last years, everolimus - a m-TOR inhibitor (Afinitor (R)) - and sunitinib (Sutent (R)) - a multi-kinase inhibitor - have shown their antiproliferative potential to treat symptomatic and asymptomatic patients with pancreatic NET. In the last year two phase III multicenter trials have been published or have been presented. The RADIANT-4 study have shown an improvement in progression free survival in asymptomatic patients with progressive gastrointestinal NET, lung-NET and NET cancer patients with unknown primary treated with everolimus. In addition, the NETTER-1 trial as the first randomised controlled multi-center trial has investigated the potential of peptide receptor radiotherapy with a radiolabelled somatostatin-analogue in symptomatic and asymptomatic patients with progressive midgut NET. The present paper summarizes their results and draws possible implications for daily routine use.
- Find related publications in this database (Keywords)
- Everolimus
- somatostatine analogue
- radio-labelled therapy